PERSONAL INFORMATION
Name: Xiaokui Tang
Gender: female
Title: professor
Position: chief physician
CONTACT INFORMATION
Email: txk1200@126.com
Address: The First Affiliated Hospital of Chongqing Medical University
Phone: +86-15909361379
EDUCATION EXPERIENCE
graduated from Chongqing Medical University in 1995 and obtained a medical doctoral degree in 2009.
2007-2008, have visited and studied at the Paris Descartes University in Paris, France from
2015-2016, have visited and studied at Peking Union Medical College Hospital.
WORKING EXPERIENCE
1995-2001, Resident Physician, Respiratory Medicine Department, The First Affiliated Hospital of Chongqing Medical University
2001-2007, attending physician and lecturer in the Department of Respiratory Medicine, The First Affiliated Hospital of Chongqing Medical University
2007-2009, Deputy Chief Physician of Respiratory Medicine Department, The First Affiliated Hospital of Chongqing Medical University
2009-2015, Associate Professor of Respiratory Medicine, The First Affiliated Hospital of Chongqing Medical University
2015-2017, Chief Physician of Respiratory Medicine Department, The First Affiliated Hospital of Chongqing Medical University
2017-present, Professor of Respiratory Medicine, The First Affiliated Hospital of Chongqing Medical University
RESEARCH INTERESTS
Be familiar with the diagnosis and treatment in respiratory medicine, such as interstitial lung disease, chronic obstructive pulmonary disease, lung cancer, pulmonary infectious diseases, pleural disease, tuberculosis, etc.
HONOUR & AWARDS
1. Communication editorial board member of International Journal of Respiration
2. Member of the Cancer Prevention and Treatment Science Popularization Committee of the China Anti Cancer Association
3. Member of the Second Elderly and Respiratory Critical Illness Special Committee of the Chinese Gerontology Geriatrics Committee
4. Leader of the Interstitial Pulmonary Disease Study Group of the Respiratory Physician Branch of the Chongqing Physician Association
5. Member of the Chongqing Working Group of the Respiratory Disease Branch of the China Rare Disease Alliance
PUBLICATIONS
Main papers published as corresponding authors:
1. Almonertinib-induced interstitial lung disease in a lung adenocarcinoma patient complicated with interstitial lung abnormality. BMC pulmonary medicine,2023,23(1).
2. A prognostic analysis of antisynthetase syndrome-related interstitial lung disease. International journal of rheumatic diseases,2022,25(12).
3. Clinical characteristics and prognostic analysis of microscopic polyangiitis with diffuse alveolar haemorrhage. The Journal of Rheumatology 2021,48:1-7
4. Current and emerging treatment options for lung cancer in patients with pre-existing connective tissue disease.Pulmonary Pharmacology &Therapcutics 63(2020) 10937.
5. The RNA binding protein Tristetraprolin down-regulates autophagy in lung adenocarcinoma cells. Exp Cell Res. 367 (2018) 89–96.
6. The role of circulating tumor cells in evaluation of prognosis and treatment response in advanced non-small-cell lung cancer. Cancer Chemotherapy and Pharmacology 2017:79:825-833.
7. Circulating tumor cells in lung cancer: detection methods and clinical applications. Lung 2015;193:157-171.
8. 63例肌炎自身抗体阳性间质性肺疾病的临床特点分析. 解放军医学杂志,2021,46(02):142-148.
9. 循环肿瘤细胞在肺癌精准医疗中的研究进展.中国肿瘤临床,2021,48(20):1071-1074.
10. 吗替麦考酚酯治疗系统性硬化相关间质性肺病疗效Meta分析.中国免疫学杂志,2020,(17):2136-2141.
11. Tristetraprolin通过NF-kB通路抑制肺腺癌细胞自噬.南方医科大学学报,2019,39(03):313-319.
12. 显微镜下多血管炎肺部病变临床回顾性研究（附94例报告）. 重庆医科大学学报, 2018-06-15. DOI：10.13406/j.cnki.cyxb.001791.
13. 无创正压通气治疗慢性阻塞性肺疾病急性加重并急性呼吸衰竭失败的危险因素分析. 华西医学,2017,32(11):1702-1707.
14. 结缔组织疾病相关间质性肺疾病219例临床分析.四川医学,2017,38（3）：305-310.
